KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Enterprise Value (2018 - 2025)

Castle Biosciences' Enterprise Value history spans 7 years, with the latest figure at -$299.5 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 2.17% year-over-year to -$299.5 million; the TTM value through Dec 2025 reached -$299.5 million, down 2.17%, while the annual FY2025 figure was -$299.5 million, 2.17% down from the prior year.
  • Enterprise Value for Q4 2025 was -$299.5 million at Castle Biosciences, down from -$287.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$225.5 million in Q2 2023 and bottomed at -$407.0 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$275.6 million (2025), against an average of -$285.8 million.
  • The largest annual shift saw Enterprise Value tumbled 312.54% in 2021 before it grew 26.76% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$329.6 million in 2021, then rose by 21.54% to -$258.6 million in 2022, then increased by 6.0% to -$243.1 million in 2023, then fell by 20.58% to -$293.1 million in 2024, then decreased by 2.17% to -$299.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Enterprise Value are -$299.5 million (Q4 2025), -$287.5 million (Q3 2025), and -$275.9 million (Q2 2025).